Tracers / [177Lu]Lu-DTPA-anti-TRA
[177Lu]Lu-DTPA-anti-TRA
Also written as [Lu-177]Lu-DTPA-anti-TRA
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical
- Syntheses indexed
- 0
What it is
- Compound class
- scFv-Fc antibody fragment radioconjugate (CHX-A″-DTPA-conjugated)
- Target / mechanism
- TRA-1-60, a cancer stemness marker PMID 42687978
- Clinical application
- Pancreatic cancer PMID 42687978
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
No synthesis has been parsed for this agent yet.
Need this precursor?We can point you to suppliers for [177Lu]Lu-DTPA-anti-TRA, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.